Arbutus Biopharma Corp (NASDAQ: ABUS) kicked off on Friday, down -0.30% from the previous trading day, before settling in for the closing price of $3.30. Over the past 52 weeks, ABUS has traded in a range of $2.30-$4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 68.89% over the past five years. While this was happening, its average annual earnings per share was recorded 11.82%. With a float of $147.43 million, this company’s outstanding shares have now reached $189.44 million.
Let’s look at the performance matrix of the company that is accounted for 73 employees. In terms of profitability, gross margin is 84.13%, operating margin of -1223.89%, and the pretax margin is -1137.64%.
Arbutus Biopharma Corp (ABUS) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arbutus Biopharma Corp is 22.20%, while institutional ownership is 54.95%. The most recent insider transaction that took place on Feb 04 ’25, was worth 72,827. In this transaction Chief Financial Officer of this company sold 22,183 shares at a rate of $3.28, taking the stock ownership to the 159,724 shares. Before that another transaction happened on Feb 04 ’25, when Company’s Chief Medical Officer sold 19,348 for $3.28, making the entire transaction worth $63,519. This insider now owns 106,194 shares in total.
Arbutus Biopharma Corp (ABUS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.33% during the next five years compared to 18.41% growth over the previous five years of trading.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Take a look at Arbutus Biopharma Corp’s (ABUS) current performance indicators. Last quarter, stock had a quick ratio of 7.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 92.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (NASDAQ: ABUS) saw its 5-day average volume 0.4 million, a negative change from its year-to-date volume of 0.69 million. As of the previous 9 days, the stock’s Stochastic %D was 25.05%. Additionally, its Average True Range was 0.13.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 14.53%, which indicates a significant decrease from 26.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.32% in the past 14 days, which was higher than the 39.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.36, while its 200-day Moving Average is $3.55. Nevertheless, the first resistance level for the watch stands at $3.36 in the near term. At $3.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.48. If the price goes on to break the first support level at $3.23, it is likely to go to the next support level at $3.17. Assuming the price breaks the second support level, the third support level stands at $3.11.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
The company with the Market Capitalisation of 623.42 million has total of 189,492K Shares Outstanding. Its annual sales at the moment are 18,140 K in contrast with the sum of -72,850 K annual income. Company’s last quarter sales were recorded 1,340 K and last quarter income was -19,720 K.
